Novonordisk Pharmaceuticals' Rare Disease Division announced on April 17, World Hemophilia Day, that it donated knee braces for joint protection and keyrings handmade by employees to the Korea Kohem Association, a gathering of hemophilia patients and their families.
Sasha Semientchuk, CEO of Novo Nordisk Pharmaceuticals (left), and Hanjin Park, President of the Korea Hemophilia Association, are posing for a commemorative photo at the knee brace and keyring donation ceremony. [Photo by Novo Nordisk Pharmaceuticals]
Hemophilia is a rare disease caused by a deficiency of blood clotting proteins, resulting in improper blood coagulation. To improve global access to hemophilia diagnosis and specialized treatment, April 17 is designated and celebrated annually as World Hemophilia Day.
Treatment methods for hemophilia continue to be developed, but patients with bleeding disorders still face difficulties in daily life and at work. Some hemophilia patients experience bleeding in joints and muscles despite regular treatment, which can lead to joint damage and pain, limiting daily activities and mobility.
Sasha Semientchuk, CEO of Novonordisk Pharmaceuticals, stated, “Novonordisk Pharmaceuticals conducted this year’s World Hemophilia Day event under the theme ‘A Better Future,’ recognizing that there are still many issues to resolve to improve the quality of life for hemophilia patients.” She added, “Novonordisk Pharmaceuticals will continue to expand correct awareness of hemophilia and strive to improve patients’ quality of life.”
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
